Form 4: Alzamend Neuro CFO David Katzoff Reports Transaction in Company Stock
SEC Form 4 Filing
David Katzoff, CFO of Alzamend Neuro, Inc., reports the acquisition of 5,000 shares of common stock at a price of $1.0096 per share on March 21, 2025.
Summary
- On March 21, 2025, David J. Katzoff, the Chief Financial Officer of Alzamend Neuro, Inc. (ALZN), acquired 5,000 shares of common stock.
- The purchase price was $1.0096 per share.
- Following the transaction, Katzoff directly owns 5,540 shares of Alzamend Neuro, Inc.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a stock transaction by a company insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, like the CFO, transacts in their company's stock. It provides transparency to the market regarding the actions of company executives.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it provides insight into the actions of a key executive.
Key Dates
| Date | Description |
|---|---|
| 03/21/2025 | Date of stock transaction: David Katzoff acquired 5,000 shares of Alzamend Neuro, Inc. common stock. |
| 03/24/2025 | Date of signature for the Form 4 filing. |
Keywords
Alzamend Neuro, ALZN, Form 4, Insider Trading, David Katzoff, CFO, Stock Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.